Implementation and performance evaluation of PAS-X MES in GMP-regulated pharmaceutical manufacturing

Pharmaceutical industry works under the strict Good Manufacturing Practice (GMP) conditions which require strong systems to guarantee the quality of the product, integrity of data and adherence to regulations. Manufacturing Execution Systems (MES) have become one of such key tools in the realization of such goals. The purpose of the study is to assess the application and functioning of PAS X MES among the GMP-regulated manufacturing facilities, in particular, its operational effectiveness, compliance benefits, as well as difficulties faced. Multi-site observational analysis was used where site survey, system audit data and key stakeholder interviews were used. Pre- and post- implementation performance measures were measured quantitatively. The outcomes have shown 25 percent decrease in the batch cycle time, increasing Right First Time rates to 95 percent and a drop in process deviations by 66.7 percent. The metrics on compliance were highly improved where there was a 100 percent compliance with the 21 CFR Part 11 standard on the use of electronic signatures and the audit score has improved by 38.5 percent. Additionally, the time taken in review by QA per batch decreased by 62.5 percent making the processes of release of batches faster. Along with these improvements, issues that included spending more time with the validation in the first place and the reluctance of the users in the beginning made clear the necessity of a proper management of the change. Comparative study with other MES systems determined that the implementation speed and user satisfaction characterized PAS X with competitive advantage. This paper highlights PAS X MES as a game-changer to GMP-compliant pharmaceutical manufacturing, which can bring organizational operational agility and digital maturity to Pharma 4.0 movements.